The NCT05498428 is focused on evaluating the efficacy and safety of Amivantamab in patients with advanced or metastatic solid tumors, including those with specific EGFR mutations such as the EGFR exon 20 insertion in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.